Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (January 2022)
37 slides from Adocia SA's investor presentation, January 2022

Slide 1: Corporate Presentation
Corporate Presentation January 2022

Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those

Slide 3: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO Director of R&D Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-fou

Slide 4: Executive Summary
Executive Summary Our mission: to develop innovative treatments involving 1 approved hormones for the treatment of diabetes and obesity 2 Our business model: product licensing after proof-of-concept Our pipeline is based on our 3 patented technology platforms: 3 • 1 product approved to enter in Phas

Slide 5: Adocia's vision: addressing metabolic diseases from hormonal to cell therapies
Adocia’s vision: addressing metabolic diseases from hormonal to cell therapies Cell therapy for chronic diseases cure e.g. hydrogel matrix for islets transplants Oral Formulations for diabetes and obesity Hormones combinations for diabetes and obesity e.g. M1Pram, PramExe Improved insulin-therapy e.

Slide 6: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 463 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese • Several hormones are involved in both diabetes and obesity treatment 1.

Slide 7: A well-advanced and diversified pipeline with products ready to partner
A well-advanced and diversified pipeline with products ready to partner Preclinic Phase 1 Phase 2 Phase 3 Upcoming milestones BC Lispro Phase 3 in China expected in 2022 Ultra-Rapid Insulin U100 / U200 Phase 3 in USA and Europe expected in 2022* Insulins Combination BC Combo U200 Phase 1 expected in

Slide 8: BioChaperone platform potentializes performance of insulins and other hormones
BioChaperone® platform (BC) potentializes performance of insulins and other hormones BioChaperone® Proteins and peptides (insulin, amylin, GLP-1 RA, glucagon…) • Pharmaceutical excipient • 50 patents filed [BioChaperone® Protein] Complex Improved solubility Accelerated absorption Improved stabil

Slide 9: Diabetes
Diabetes Corporate Presentation 9

Slide 10: BioChaperone Lispro
BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control Corporate Presentation 10

Slide 11: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators • Good tolerance for optimized daily use AUC0-2h: -61%* • Range of strengths (U100

Slide 12: BC Lispro, a competitor in the Ultra-Rapid Insulins class
BC Lispro, a competitor in the Ultra-Rapid Insulins class Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization for Chi

Slide 13: BC Combo: basal-bolus insulin combination
BC Combo: basal-bolus insulin combination Insulins glargine & lispro Corporate Presentation 13

Slide 14: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia Simple Affordable Less hypoglycemia Limited number of injections

Slide 15: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2,7bn1 Western Markets: T2D patients • $40m upfront $2,3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D ~65% • Double-digit royalties on sales patients Market share in India and China (volume)

Slide 16: Multi-hormonal combinations
Multi-hormonal combinations Insulin in combination with other hormones Corporate Presentation 16

Slide 17: Adocia has in hand the next generation of insulin-based treatment
Adocia has in hand the next generation of insulin-based treatment Multi-hormonal combinations Medical M1Pram, BC LisPram/ benefits BC AsPram Ultra-Rapid Insulins BC Lispro, Fiasp®, Lyumjev® Rapid Acting Insulins Humalog®, Novolog® & biosimilars Human Insulins Animal Insulins Humulin®, Novolin® Hypur

Slide 18: M1Pram, BC LisPram / BC AsPram
M1Pram BC LisPram / BC AsPram Insulin-Amylin 2-in-1 products: a therapeutic breakthrough Corporate Presentation 18

Slide 19: Glycemic control requires the synchronized action of insulin and amylin
Glycemic control requires the synchronized action of insulin and amylin Meal Without diabetes Pancreas Insulin Level of secretion (relative scale) Amylin Insulin Glucagon Produced 0 1 2 3 4 5 6 Produced Glucagon by α-cells Time (hours) by β-cells Meal With diabetes Level of secretion Glucagon is dys

Slide 20: Symlin (pramlintide) was approved by FDA in 2005 as an adjunct to insulin
Symlin® (pramlintide, an amylin analog) was approved by FDA in 2005 as an adjunct to insulin treatment for T1D and T2D The amylin effects in physiology The evidences demonstrated by pramlintide Activates amylin receptors in different brain areas Satiety Improvement of HbA1c Protects cognitive

Slide 21: Adocia is developing insulin-amylin combinations for pen and pump
Adocia is developing insulin-amylin combinations for pen and pump Optimal product profile for MDI in pen Optimal product profile for pump Regular insulin analog + Pram Rapid insulin analog + Pram M1Pram BC LisPram BC AsPram Q1 2022: Phase 2 T1D results Q2 2022: Phase 1 T1D results MDI: Multiple Dail

Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog
Promising Phase 1b results of M1Pram in pen vs Novolog Phase 1b – CT038: n=40 T1D 3-week outpatient trial - M1Pram vs. Novolog (Part B n=16; High dose of insulin) Average glycemia Weight Time In Range 164 0,5 16,2 162 0,4 16 0 15,8 160 -7 mg/dL -2 kg 15,6 +58 min -0,5 Hours 158 mg/dL p=0,01 p=0,0065

Slide 23: M1Pram offers better glycemic control and weight loss
M1Pram offers better glycemic control and weight loss M1Pram leverages pramlintide’s clinical benefits “This combination has the potential to Targeted phase 2 results: finally deliver on the promise of pramlintide for a large number of patients.” HbA1c decrease: [-0,3% ; -0,5%] Prof. Robert Ratner

Slide 24: BC LisPram: the optimal combination for pumps
BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, by Dr. Ahmad Haidar, comparing Lispro in one pump vs. Lispro and Pramlintide administered simultaneously in two separate pumps, over one month1 n=29 T1D Results • 10% improvement of Tim

Slide 25: Cell Therapy
Cell Therapy Innovative Scaffold for Pancreatic Cell Therapy Corporate Presentation 25

Slide 26: Innovative hydrogel scaffold to protect and host islets transplants
Adocia developed an innovative hydrogel scaffold to protect and host islets of Langherans transplants Hydrogel scaffold Transplant Organoid Islets sourcing (Allogenic/stem-cell) External source Adocia’s goal is to propose a life saving therapy to insulino-resistant patients Corporate Presentation 26

Slide 27: Hydrogel development achievements
Development achievements Innovative Hydrogel Well tolerated Insulin secretion Encapsulated Islets in response to glucose Naked Islets Long term stability and fully retrievable Patents application filed 3G 15G 3G 6 Islets encapsulation Normalized insulin secretion 5 Simple and cell-friendly p

Slide 28: Obesity
Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” Corporate Presentation 29

Slide 29: Combinations of diabetes hormones as a way to treat obesity
Combinations of “diabetes” hormones appears to be a revolutionary way to treat obesity Product Class Mean Mean Weight Loss Weight Loss expected Targeted (standalone) (combo) AMYLIN PramExe Amylin analog -7,9%1 -15% Pramlintide Exenatide GLP1-RA - 8%2 Diabetes GLP-1 Obesity BC GluExe Glucagon -7 to -

Slide 30: First Proof-of-Concept in obese mice with BC Glucagon Exenatide
A first Proof-of-Concept has been established in obese mice with Biochaperone® Glucagon Exenatide (BC GluExe) 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showe

Slide 31: Adocia is developing patient-centric treatments
Adocia is developing patient-centric treatments CURRENT PARADIGM ADOCIA’S PARADIGM Long acting GLP-1 RA are being developed to limit the The patient wears a patch-pump number of injections to deliver combinations of short acting hormones However, despite demonstrated efficacy, GLP-1 RA class goes al

Slide 32: Patient's reasons to adopt short-acting hormones in pump
Patient’s reasons to adopt short-acting hormones in pump n days infusion n days infusion 1 day off Concentration 4x Patient can: • Intensify the treatment by increasing Concentration 2x the dosage to obtain maximum results Concentration 1x • Stop temporarily by switching it off, to suspend immediate

Slide 33: Financial & news flow
Financial & news flow Corporate Presentation 34

Slide 34: News flow
News flow BC Lispro M1Pram PramExe – BC GluExe • In China: Phase 3 start • Phase 2 study in T1D in MDI • In-Human Proof-of-concept expected in 2022 (Multiple Daily Injection) in 2022 ongoing • In USA/EU: Phase 3 launch scheduled in 2022 • Results expected Q1 2022 Cell Therapy • FIH study 2022 BC Com

Slide 35: Key financials & shareholder information
Key financials & shareholder information Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception Soula Family • 7.2m shares outstanding • $120m received from partnership 22,5% • ADR program in the US (ADOCY) E

Slide 36: Summary
Summary • A well-advanced and diversified pipeline with products ready-to-license: • 5 products with clinical proof-of-concept based on its proprietary BioChaperone® platform o BC Lispro is approved to enter in Phase 3 in China and Adocia is seeking partners for Europe, US, Japan o BC Combo clinical

Slide 37: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025